Company Filing History:
Years Active: 2023
Title: Max Echterling: Innovator in Genome Editing
Introduction
Max Echterling is a prominent inventor based in Baltimore, MD (US). He has made significant contributions to the field of genome editing, particularly in the development of innovative solutions for managing hypercholesterolemia.
Latest Patents
Echterling holds a patent for "PCSK9 endonuclease variants, compositions, and methods of use." This patent provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further includes genome-edited cells aimed at the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or related conditions. He has 1 patent to his name.
Career Highlights
Max Echterling is currently employed at 2seventy Bio, Inc., where he continues to push the boundaries of genetic research and innovation. His work focuses on developing advanced therapeutic strategies that leverage genome editing technologies.
Collaborations
Echterling collaborates with talented professionals in his field, including colleagues Jordan Jarjour and Kyle Havens. Their combined expertise fosters a dynamic environment for innovation and research.
Conclusion
Max Echterling is a key figure in the realm of genome editing, with a focus on addressing critical health issues through innovative solutions. His contributions are paving the way for advancements in genetic therapies.